Published in Genes Dev on December 15, 2009
The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol (2012) 7.32
Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell (2011) 7.02
MicroRNAs in stress signaling and human disease. Cell (2012) 6.93
Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov (2010) 6.07
miRNAs in human cancer. J Pathol (2010) 6.02
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med (2012) 5.46
Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer (2011) 5.12
Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet (2011) 4.81
The microcosmos of cancer. Nature (2012) 4.50
Desperately seeking microRNA targets. Nat Struct Mol Biol (2010) 3.85
MicroRNAs in cancer. Annu Rev Pathol (2013) 3.50
MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov (2013) 3.33
MicroRNAs in human cancer. Adv Exp Med Biol (2013) 3.19
Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell (2012) 3.10
microRNA involvement in human cancer. Carcinogenesis (2012) 2.98
Widespread regulatory activity of vertebrate microRNA* species. RNA (2010) 2.97
Transcriptome-wide miR-155 binding map reveals widespread noncanonical microRNA targeting. Mol Cell (2012) 2.54
The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ (2013) 2.41
Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol (2010) 2.40
MicroRNA miR-125b causes leukemia. Proc Natl Acad Sci U S A (2010) 2.29
The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res (2010) 2.13
Germline deletion of the miR-17∼92 cluster causes skeletal and growth defects in humans. Nat Genet (2011) 2.04
Inhibition of microRNA function by antimiR oligonucleotides. Silence (2012) 2.02
MicroRNA-17~92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways. EMBO J (2013) 2.01
Roles of small RNAs in tumor formation. Trends Mol Med (2010) 1.89
Adult-specific functions of animal microRNAs. Nat Rev Genet (2013) 1.89
The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res (2010) 1.88
Molecular dissection of the miR-17-92 cluster's critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation. Blood (2011) 1.80
MiR-93 enhances angiogenesis and metastasis by targeting LATS2. Cell Cycle (2012) 1.74
The role of miRNAs in regulating gene expression networks. J Mol Biol (2013) 1.74
Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol (2013) 1.73
miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma. Genes Dev (2011) 1.66
The miR-17-92 cluster of microRNAs confers tumorigenicity by inhibiting oncogene-induced senescence. Cancer Res (2010) 1.60
Myc: Maestro of MicroRNAs. Genes Cancer (2010) 1.58
Small nucleolar RNA 42 acts as an oncogene in lung tumorigenesis. Oncogene (2011) 1.54
Causes and consequences of microRNA dysregulation. Cancer J (2012) 1.51
The biological functions of miRNAs: lessons from in vivo studies. Trends Cell Biol (2014) 1.47
A miR-19 regulon that controls NF-κB signaling. Nucleic Acids Res (2012) 1.43
The microRNA-17-92 family of microRNA clusters in development and disease. Cancer J (2012) 1.42
MicroRNAs MiR-17, MiR-20a, and MiR-106b act in concert to modulate E2F activity on cell cycle arrest during neuronal lineage differentiation of USSC. PLoS One (2011) 1.40
Tumor suppressor p53 meets microRNAs. J Mol Cell Biol (2011) 1.39
MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. Cancer Cell (2014) 1.36
Genetic and epigenetic alterations in pancreatic carcinogenesis. Curr Genomics (2011) 1.33
miR-17-92 cluster: ups and downs in cancer and aging. Biogerontology (2010) 1.32
mir-17-92: a polycistronic oncomir with pleiotropic functions. Immunol Rev (2013) 1.32
Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression. Cancer Res (2013) 1.28
Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. J Exp Med (2011) 1.27
MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sézary syndrome. Cell Death Dis (2011) 1.25
STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res (2011) 1.24
MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1. Cell Death Dis (2014) 1.24
PTEN: Multiple Functions in Human Malignant Tumors. Front Oncol (2015) 1.24
Tumorigenicity of the miR-17-92 cluster distilled. Genes Dev (2010) 1.22
miRNAs as modulators of angiogenesis. Cold Spring Harb Perspect Med (2013) 1.21
A component of the mir-17-92 polycistronic oncomir promotes oncogene-dependent apoptosis. Elife (2013) 1.20
Mir-17-3p controls spinal neural progenitor patterning by regulating Olig2/Irx3 cross-repressive loop. Neuron (2011) 1.20
MicroRNA cluster miR-17-92 regulates neural stem cell expansion and transition to intermediate progenitors in the developing mouse neocortex. Cell Rep (2013) 1.20
Temporal expression of microRNA cluster miR-17-92 regulates effector and memory CD8+ T-cell differentiation. Proc Natl Acad Sci U S A (2012) 1.20
miR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth. Nat Commun (2015) 1.18
Rapid generation of microRNA sponges for microRNA inhibition. PLoS One (2012) 1.17
The use of miRNA microarrays for the analysis of cancer samples with global miRNA decrease. RNA (2013) 1.16
MicroRNA and transcription factor co-regulatory network analysis reveals miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia. Nucleic Acids Res (2012) 1.15
MicroRNA regulation of T-cell differentiation and function. Immunol Rev (2013) 1.13
The c-Myc-regulated microRNA-17~92 (miR-17~92) and miR-106a~363 clusters target hCYP19A1 and hGCM1 to inhibit human trophoblast differentiation. Mol Cell Biol (2013) 1.12
Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer. Cancer Res (2010) 1.12
Shielding the messenger (RNA): microRNA-based anticancer therapies. Pharmacol Ther (2011) 1.12
Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. Oncogene (2011) 1.11
miR-99a/100~125b tricistrons regulate hematopoietic stem and progenitor cell homeostasis by shifting the balance between TGFβ and Wnt signaling. Genes Dev (2014) 1.11
A p21-ZEB1 complex inhibits epithelial-mesenchymal transition through the microRNA 183-96-182 cluster. Mol Cell Biol (2013) 1.10
miR-26a suppresses tumor growth and metastasis by targeting FGF9 in gastric cancer. PLoS One (2013) 1.09
MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. Leukemia (2014) 1.08
MicroRNA in the adaptive immune system, in sickness and in health. J Clin Immunol (2010) 1.07
Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS One (2011) 1.07
Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells. J Gastroenterol (2012) 1.07
B-cell malignancies in microRNA Eμ-miR-17~92 transgenic mice. Proc Natl Acad Sci U S A (2013) 1.06
Exosomal miRNAs as Biomarkers for Prostate Cancer. Front Genet (2013) 1.06
Fractionated radiation alters oncomir and tumor suppressor miRNAs in human prostate cancer cells. Radiat Res (2012) 1.06
MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications. Genome Med (2013) 1.05
Viral-mediated noisy gene expression reveals biphasic E2f1 response to MYC. Mol Cell (2011) 1.03
The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells. J Virol (2012) 1.03
miR-146a promotes the initiation and progression of melanoma by activating Notch signaling. Elife (2014) 1.02
MicroRNA in cancer: new hopes for antineoplastic chemotherapy. Ups J Med Sci (2012) 0.98
Oncogenic cooperation between SOCS family proteins and EGFR identified using a Drosophila epithelial transformation model. Genes Dev (2012) 0.97
MicroRNAs in cancer therapeutic response: Friend and foe. World J Clin Oncol (2014) 0.96
The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop. Blood (2013) 0.96
Regulation of B-cell development and function by microRNAs. Immunol Rev (2013) 0.95
Targeting of TGFβ signature and its essential component CTGF by miR-18 correlates with improved survival in glioblastoma. RNA (2012) 0.95
Novel direct targets of miR-19a identified in breast cancer cells by a quantitative proteomic approach. PLoS One (2012) 0.95
Targeting MYC-Regulated miRNAs to Combat Cancer. Genes Cancer (2010) 0.94
MicroRNAs in Cancer Biology and Therapy: Current Status and Perspectives. Genes Dis (2014) 0.94
MYC and the art of microRNA maintenance. Cold Spring Harb Perspect Med (2014) 0.94
miR-223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions. PLoS One (2014) 0.94
Dysregulation of microRNA biogenesis in cancer: the impact of mutant p53 on Drosha complex activity. J Exp Clin Cancer Res (2016) 0.94
miR-18a inhibits CDC42 and plays a tumour suppressor role in colorectal cancer cells. PLoS One (2014) 0.93
Posttranscriptional regulation of PTEN dosage by noncoding RNAs. Sci Signal (2010) 0.93
Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis. Haematologica (2010) 0.93
High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS One (2014) 0.93
miR-17 extends mouse lifespan by inhibiting senescence signaling mediated by MKP7. Cell Death Dis (2014) 0.93
Focus on PTEN Regulation. Front Oncol (2015) 0.93
MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor gene. Breast Cancer Res (2015) 0.92
An allelic series of miR-17 ∼ 92-mutant mice uncovers functional specialization and cooperation among members of a microRNA polycistron. Nat Genet (2015) 0.92
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
Combinatorial microRNA target predictions. Nat Genet (2005) 50.48
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature (2005) 48.95
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell (2007) 38.42
Human MicroRNA targets. PLoS Biol (2004) 34.51
The impact of microRNAs on protein output. Nature (2008) 32.39
c-Myc-regulated microRNAs modulate E2F1 expression. Nature (2005) 31.81
Widespread changes in protein synthesis induced by microRNAs. Nature (2008) 31.44
The microRNA.org resource: targets and expression. Nucleic Acids Res (2007) 16.26
Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell (2005) 15.26
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature (1986) 14.56
Pten is essential for embryonic development and tumour suppression. Nat Genet (1998) 13.41
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell (2008) 12.29
A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res (2005) 10.46
Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol (2008) 10.42
Tenets of PTEN tumor suppression. Cell (2008) 8.61
miRiad roles for the miR-17-92 cluster in development and disease. Cell (2008) 8.02
Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res (2004) 7.96
Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A (1999) 7.88
MicroRNAs and cancer: short RNAs go a long way. Cell (2009) 7.25
High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol (1998) 6.38
Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One (2008) 3.68
Vagaries of conditional gene targeting. Nat Immunol (2007) 3.51
The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc Natl Acad Sci U S A (2009) 2.72
A microRNA cluster as a target of genomic amplification in malignant lymphoma. Leukemia (2005) 2.19
Human MicroRNA targets. PLoS Biol (2004) 34.51
A mammalian microRNA expression atlas based on small RNA library sequencing. Cell (2007) 34.03
Integration of biological networks and gene expression data using Cytoscape. Nat Protoc (2007) 27.10
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
MicroRNA targets in Drosophila. Genome Biol (2003) 23.59
Global mapping of the yeast genetic interaction network. Science (2004) 21.34
International network of cancer genome projects. Nature (2010) 20.35
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
BIND: the Biomolecular Interaction Network Database. Nucleic Acids Res (2003) 18.75
The microRNA.org resource: targets and expression. Nucleic Acids Res (2007) 16.26
The HUPO PSI's molecular interaction format--a community standard for the representation of protein interaction data. Nat Biotechnol (2004) 16.08
Characterizing gene sets with FuncAssociate. Bioinformatics (2003) 14.10
Identification of microRNAs of the herpesvirus family. Nat Methods (2005) 12.98
Identification of virus-encoded microRNAs. Science (2004) 12.56
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res (2011) 10.99
The BioPAX community standard for pathway data sharing. Nat Biotechnol (2010) 9.19
Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res (2010) 9.18
A novel class of small RNAs bind to MILI protein in mouse testes. Nature (2006) 8.80
The Systems Biology Graphical Notation. Nat Biotechnol (2009) 8.53
Mutual exclusivity analysis identifies oncogenic network modules. Genome Res (2011) 7.22
Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol (2010) 7.15
Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A (2007) 6.79
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A (2009) 6.78
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
Emerging landscape of oncogenic signatures across human cancers. Nat Genet (2013) 6.48
miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol (2004) 6.44
The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol (2007) 6.16
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Pathguide: a pathway resource list. Nucleic Acids Res (2006) 6.05
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
MicroRNA profiling of the murine hematopoietic system. Genome Biol (2005) 4.94
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
Protein 3D structure computed from evolutionary sequence variation. PLoS One (2011) 4.71
Comprehensive evaluation of differential gene expression analysis methods for RNA-seq data. Genome Biol (2013) 4.67
Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun (2013) 4.35
Functional copy-number alterations in cancer. PLoS One (2008) 4.27
Direct-coupling analysis of residue coevolution captures native contacts across many protein families. Proc Natl Acad Sci U S A (2011) 4.08
Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med (2008) 3.98
Antisense-mediated depletion reveals essential and specific functions of microRNAs in Drosophila development. Cell (2005) 3.95
A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res (2008) 3.93
Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol (2009) 3.66
Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood (2007) 3.64
Automated network analysis identifies core pathways in glioblastoma. PLoS One (2010) 3.64
A series of PDB related databases for everyday needs. Nucleic Acids Res (2010) 3.60
The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res (2007) 3.55
Determinants of protein function revealed by combinatorial entropy optimization. Genome Biol (2007) 3.46
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet (2011) 3.41
Target mRNA abundance dilutes microRNA and siRNA activity. Mol Syst Biol (2010) 3.37
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell (2012) 3.37
Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell (2010) 3.34
Characterization of small RNAs in Aplysia reveals a role for miR-124 in constraining synaptic plasticity through CREB. Neuron (2009) 3.27
A non-genetic route to aneuploidy in human cancers. Nat Cell Biol (2011) 3.25
cPath: open source software for collecting, storing, and querying biological pathways. BMC Bioinformatics (2006) 3.24
A specificity map for the PDZ domain family. PLoS Biol (2008) 3.16
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest (2009) 3.14
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov (2012) 3.04
Three-dimensional structures of membrane proteins from genomic sequencing. Cell (2012) 3.02
CancerGenes: a gene selection resource for cancer genome projects. Nucleic Acids Res (2006) 3.00
Pathway information for systems biology. FEBS Lett (2005) 2.97
Widespread regulatory activity of vertebrate microRNA* species. RNA (2010) 2.97
The developmental miRNA profiles of zebrafish as determined by small RNA cloning. Genes Dev (2005) 2.94
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A (2012) 2.89
SeqHound: biological sequence and structure database as a platform for bioinformatics research. BMC Bioinformatics (2002) 2.84
Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov (2014) 2.79
Introducing meta-services for biomedical information extraction. Genome Biol (2008) 2.78
A role for neuronal piRNAs in the epigenetic control of memory-related synaptic plasticity. Cell (2012) 2.72
Evaluation of annotation strategies using an entire genome sequence. Bioinformatics (2003) 2.66
NetPath: a public resource of curated signal transduction pathways. Genome Biol (2010) 2.62
Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol (2002) 2.61
Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc Natl Acad Sci U S A (2013) 2.57
The amino-acid mutational spectrum of human genetic disease. Genome Biol (2003) 2.55
A p53-p66Shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stress-induced apoptosis. Oncogene (2002) 2.55
Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature (2007) 2.54
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet (2009) 2.51
Protein structure prediction from sequence variation. Nat Biotechnol (2012) 2.50
DGCR8-dependent microRNA biogenesis is essential for skin development. Proc Natl Acad Sci U S A (2008) 2.49
RNA targets of wild-type and mutant FET family proteins. Nat Struct Mol Biol (2011) 2.46
Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res (2007) 2.44
CXCR4 is required for the quiescence of primitive hematopoietic cells. J Exp Med (2008) 2.41
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A (2009) 2.35
Models from experiments: combinatorial drug perturbations of cancer cells. Mol Syst Biol (2008) 2.33
Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am J Hum Genet (2005) 2.29
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res (2013) 2.26
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A (2009) 2.09
Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res (2011) 2.06
Germline deletion of the miR-17∼92 cluster causes skeletal and growth defects in humans. Nat Genet (2011) 2.04
Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. PLoS Genet (2011) 2.00
The MAPK(ERK-1,2) pathway integrates distinct and antagonistic signals from TGFalpha and FGF7 in morphogenesis of mouse mammary epithelium. Dev Biol (2007) 1.98
Dual mode of degradation of Cdc25 A phosphatase. EMBO J (2002) 1.95